INX 3280

Drug Profile

INX 3280

Alternative Names: LR 3280; TA 3280

Latest Information Update: 09 Dec 2004

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Unknown
  • Developer Inex Pharmaceuticals Corporation; Tanabe Seiyaku
  • Class Antisense oligonucleotides
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Lymphoma; Reperfusion injury; Solid tumours

Most Recent Events

  • 08 Dec 2004 Discontinued - Preclinical for Reperfusion injury in Japan (unspecified route)
  • 17 Jun 2002 Discontinued - Phase-II for Lymphoma in Canada (unspecified route)
  • 17 Jun 2002 Discontinued - Phase-II for Solid tumours in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top